Overview

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
- To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. - To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Rigel Pharmaceuticals
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions